Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics Limited has announced the details of its upcoming Annual General Meeting, scheduled for November 12, 2025, in Perth, Australia. Shareholders are encouraged to participate either in person or by proxy, with voting instructions required by November 10, 2025. The company has opted for electronic distribution of meeting materials, reflecting a modern approach to shareholder communication.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited operates in the biotechnology industry, focusing on developing therapeutic solutions for neurological conditions. The company is committed to advancing its research and development efforts to address unmet medical needs in this sector.
Average Trading Volume: 526,512
Technical Sentiment Signal: Sell
For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.